Best CAR-T Cell Therapy
Practices Released
Chimeric antigen receptor (CAR) T-cell therapy (CART) has revolutionized the management of hematological malignancies in pediatric and adult patients. In CART, a patient’s T-cells are removed through a process called apheresis. With the use of either a lentivirus or retrovirus, these T-cells are genetically altered to express a protein that targets a specific cancer type. The modified activated T-cells are infused back into the patient to seek and destroy malignant cells. Read more.

Shedding Light on Persistent Immune Thrombocytopenia
Immune thrombocytopenia is a serious hematological condition that can result in life-threatening bleeding. When it persists for 3 to 12 months following initial treatment, it is termed persistent immune thrombocytopenia (PITP). Patients with PITP are most at risk of bleeding if they have hypertension, renal insufficiency, are on an anticoagulant or antiplatelet agent, are at risk for trauma, or cannot tolerate corticosteroids. Read more.

Follicular Lymphoma Treatment Benefits Older Patients
Follicular lymphoma (FL) most often affects older adults, who are at increased risk of drug toxicity. Yet, not much is known about the efficacy and tolerability of these medications in this age group because they are often excluded from clinical trials or there are an insufficient number of older adults in these trials to draw meaningful conclusions. Read more.